Overview

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

Status:
Recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

A single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Pembrolizumab 200 mg every 3 weeks

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Pembrolizumab